T1	Participants 26 64	related cognitive deficits in patients
T2	Participants 145 210	potential side effects of hematopoietic stem cell therapy (HSCT).
T3	Participants 1060 1133	self-evaluation of cognitive functioning in daily life was generally low.
T4	Participants 365 471	cognitive deficits following HSCT for malignant diseases at an in-patient oncologic rehabilitation clinic.
